MedTrace Logo

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

NCT01445613 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1203

Last updated 2016-08-12

Study results available
· View outcomes & findings →

Summary

The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.

Conditions

  • Carotid Artery Disease
  • Stroke
  • Amaurosis Fugax
  • Transient Ischemic Attack (TIA)

Interventions

DEVICE

RX Acculink Carotid Stent System (RX Acculink)

Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • D. Christopher Metzger, MD · Wellmont Holston Valley Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-12-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01445613 on ClinicalTrials.gov